MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2

Cancer Medicine
Ruonan LiuShifen Lu

Abstract

Our study was designed to explore the association miR-335-5p and BCL2L2 and to investigate the influence of miR-335-5p/BCL2L2 axis on cisplatin-resistant ovarian cancer cells. Microarray analysis was used to determine differentially expressed microRNAs in primary and cisplatin-resistant A2780 cells. Cell function experiments were conducted to investigate the effect of miR-335-5p on the cisplatin sensitivity of A2780 cells. The targeted relationship between BCL2L2 mRNA and miR-335-5p was validated through luciferase assay. Tumor xenograft was performed to confirm the function of miR-335-5p in restoring the cisplatin sensitivity of the ovarian cancer cells. MiR-335-5p was lowly expressed in cisplatin-resistant A2780 cells. Overexpression of miR-335-5p reduced cell survival and enhanced cisplatin-induced cell apoptosis. BCL2L2 mRNA was a target of miR-335-5p, and silencing of BCL2L2 showed the similar results on the cell viability as miR-335-5p overexpression. Upregulation of miR-335-5p expression enhanced the cisplatin sensitivity of ovarian cancer cells through suppressing BCL2L2, suggesting the potential of miR-335-5p/BCL2L2 axis as a therapeutic target for the cisplatin resistance of patients with ovarian cancer.

References

Jan 23, 1999·Oncogene·G NuñezN Inohara
Jan 19, 2007·Nature Reviews. Genetics·Kevin Chen, Nikolaus Rajewsky
Oct 1, 2008·Gynecologic Oncology·Antonio SorrentinoCristiano Ferlini
Jan 22, 2009·Apoptosis : an International Journal on Programmed Cell Death·Anna FrenzelAndreas Villunger
Jun 2, 2012·The Lancet Oncology·Yi W KongMartin Bushell
Feb 1, 2014·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Angiolo GadducciIlaria Guiggi
Jul 25, 2014·European Journal of Pharmacology·Shaloam Dasari, Paul Bernard Tchounwou
Apr 26, 2016·Ecancermedicalscience·Rajitha LokadasanPranab K Prabhakaran
Mar 2, 2017·Veterinary World·B M PrajapatiJ D Chaudhari

❮ Previous
Next ❯

Citations

Jul 9, 2020·OncoTargets and Therapy·Xiyong WangZhihao Zhang
Apr 23, 2020·Cell Death & Disease·Mariusz L Hartman, Malgorzata Czyz
Oct 23, 2019·International Journal of Molecular Sciences·Jennie OngJoost Kluiver
Apr 23, 2020·Journal of Hematology & Oncology·Patrycja GralewskaAneta Rogalska
Dec 9, 2020·Critical Reviews in Oncology/hematology·Zahra Sadat RazaviHamed Mirzaei
Jan 11, 2021·Experimental and Molecular Pathology·Mohammad TaheriMarcel E Dinger
Apr 20, 2021·Frontiers in Immunology·Xueqin ZouQixiang Shao
May 29, 2021·OncoTargets and Therapy·Lingling YeQuan An Zhang
Oct 2, 2021·Journal of Ovarian Research·Meysam Moghbeli

❮ Previous
Next ❯

Datasets Mentioned

BETA
GPL16851

Methods Mentioned

BETA
transfection
PCR
xenograft

Software Mentioned

TargetScan
SPSS
GraphPad Prism
Imagene

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.